Aptose Biosciences Files 8-K on Financials
Ticker: APTOF · Form: 8-K · Filed: May 14, 2024 · CIK: 882361
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: APTO
TL;DR
APTO filed an 8-K today covering financials. Check it out.
AI Summary
Aptose Biosciences Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and based in Toronto.
Why It Matters
This 8-K filing provides investors with crucial updates on Aptose Biosciences' financial health and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
- May 14, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is to report on Aptose Biosciences Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 14, 2024.
What were Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the business address of Aptose Biosciences Inc.?
The business address of Aptose Biosciences Inc. is 251 Consumers Road, Suite 1105, Toronto, A6, M2J 4R3.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-05-14 16:15:19
Filing Documents
- f8k_051424.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 45KB
- 0001171843-24-002861.txt ( ) — 265KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_051424_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 14, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: May 14, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer